|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
intracellular
|
2 terms
|
 |
|
Biological process
|
DNA repair
|
1 term
|
 |
|
Biochemical function
|
DNA binding
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
44:10941-10946
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
|
|
A.K.Varma,
R.S.Brown,
G.Birrane,
J.A.Ladias.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The breast and ovarian tumor suppressor BRCA1 has important functions in cell
cycle checkpoint control and DNA repair. Two tandem BRCA1 C-terminal (BRCT)
domains are essential for the tumor suppression activity of BRCA1 and interact
in a phosphorylation-dependent manner with proteins involved in DNA
damage-induced checkpoint control, including the DNA helicase BACH1 and the
CtBP-interacting protein (CtIP). The crystal structure of the BRCA1 BRCT repeats
bound to the PTRVSpSPVFGAT phosphopeptide corresponding to residues 322-333 of
human CtIP was determined at 2.5 A resolution. The peptide binds to a cleft
formed by the interface of the two BRCTs in a two-pronged manner, with
phospho-Ser327 and Phe330 anchoring the peptide through extensive contacts with
BRCA1 residues. Several hydrogen bonds and salt bridges that stabilize the
BRCA1-BACH1 complex are missing in the BRCA1-CtIP interaction, offering a
structural basis for the approximately 5-fold lower affinity of BRCA1 for CtIP
compared to that of BACH1, as determined by isothermal titration calorimetry.
Importantly, the side chain of Arg1775 in the cancer-associated BRCA1 mutation
M1775R sterically clashes with the phenyl ring of CtIP Phe330, disrupting the
BRCA1-CtIP interaction. These results provide new insights into the molecular
mechanisms underlying the dynamic selection of target proteins involved in DNA
repair and cell cycle control by BRCA1 and reveal how certain cancer-associated
mutations affect these interactions.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Rappas,
A.W.Oliver,
and
L.H.Pearl
(2011).
Structure and function of the Rad9-binding region of the DNA-damage checkpoint adaptor TopBP1.
|
| |
Nucleic Acids Res, 39,
313-324.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.J.Rowling,
R.Cook,
and
L.S.Itzhaki
(2010).
Toward classification of BRCA1 missense variants using a biophysical approach.
|
| |
J Biol Chem, 285,
20080-20087.
|
 |
|
|
|
|
 |
P.R.Joseph,
Z.Yuan,
E.A.Kumar,
G.L.Lokesh,
S.Kizhake,
K.Rajarathnam,
and
A.Natarajan
(2010).
Structural characterization of BRCT-tetrapeptide binding interactions.
|
| |
Biochem Biophys Res Commun, 393,
207-210.
|
 |
|
|
|
|
 |
T.Ochi,
B.L.Sibanda,
Q.Wu,
D.Y.Chirgadze,
V.M.Bolanos-Garcia,
and
T.L.Blundell
(2010).
Structural biology of DNA repair: spatial organisation of the multicomponent complexes of nonhomologous end joining.
|
| |
J Nucleic Acids, 2010,
0.
|
 |
|
|
|
|
 |
Z.You,
and
J.M.Bailis
(2010).
DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints.
|
| |
Trends Cell Biol, 20,
402-409.
|
 |
|
|
|
|
 |
A.De Nicolo,
E.Parisini,
Q.Zhong,
M.Dalla Palma,
K.A.Stoeckert,
S.M.Domchek,
K.L.Nathanson,
M.A.Caligo,
M.Vidal,
M.E.Cusick,
and
J.E.Garber
(2009).
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
|
| |
Cancer Res, 69,
7030-7037.
|
 |
|
|
|
|
 |
I.Drikos,
G.Nounesis,
and
C.E.Vorgias
(2009).
Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
|
| |
Proteins, 77,
464-476.
|
 |
|
|
|
|
 |
M.Carvalho,
M.A.Pino,
R.Karchin,
J.Beddor,
M.Godinho-Netto,
R.D.Mesquita,
R.S.Rodarte,
D.C.Vaz,
V.A.Monteiro,
S.Manoukian,
M.Colombo,
C.B.Ripamonti,
R.Rosenquist,
G.Suthers,
A.Borg,
P.Radice,
S.A.Grist,
A.N.Monteiro,
and
B.Billack
(2009).
Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
|
| |
Mutat Res, 660,
1.
|
 |
|
|
|
|
 |
A.Kumar,
W.S.Joo,
G.Meinke,
S.Moine,
E.N.Naumova,
and
P.A.Bullock
(2008).
Evidence for a structural relationship between BRCT domains and the helicase domains of the replication initiators encoded by the Polyomaviridae and Papillomaviridae families of DNA tumor viruses.
|
| |
J Virol, 82,
8849-8862.
|
 |
|
|
|
|
 |
M.D.Petroski
(2008).
The ubiquitin system, disease, and drug discovery.
|
| |
BMC Biochem, 9,
S7.
|
 |
|
|
|
|
 |
M.L.Kilkenny,
A.S.Doré,
S.M.Roe,
K.Nestoras,
J.C.Ho,
F.Z.Watts,
and
L.H.Pearl
(2008).
Structural and functional analysis of the Crb2-BRCT2 domain reveals distinct roles in checkpoint signaling and DNA damage repair.
|
| |
Genes Dev, 22,
2034-2047.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Tischkowitz,
N.Hamel,
M.A.Carvalho,
G.Birrane,
A.Soni,
E.H.van Beers,
S.A.Joosse,
N.Wong,
D.Novak,
L.A.Quenneville,
S.A.Grist,
P.M.Nederlof,
D.E.Goldgar,
S.V.Tavtigian,
A.N.Monteiro,
J.A.Ladias,
and
W.D.Foulkes
(2008).
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
|
| |
Eur J Hum Genet, 16,
820-832.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.A.Edwards,
M.S.Lee,
S.E.Tsutakawa,
R.S.Williams,
J.A.Tainer,
and
J.N.Glover
(2008).
The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50.
|
| |
Biochemistry, 47,
11446-11456.
|
 |
|
|
|
|
 |
Y.Nominé,
M.V.Botuyan,
Z.Bajzer,
W.G.Owen,
A.J.Caride,
E.Wasielewski,
and
G.Mer
(2008).
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
|
| |
Biochemistry, 47,
9866-9879.
|
 |
|
|
|
|
 |
Y.Shen,
and
L.Tong
(2008).
Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.
|
| |
Biochemistry, 47,
5767-5773.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Ababou,
and
J.E.Ladbury
(2007).
Survey of the year 2005: literature on applications of isothermal titration calorimetry.
|
| |
J Mol Recognit, 20,
4.
|
 |
|
|
|
|
 |
M.A.Carvalho,
S.M.Marsillac,
R.Karchin,
S.Manoukian,
S.Grist,
R.F.Swaby,
T.P.Urmenyi,
E.Rondinelli,
R.Silva,
L.Gayol,
L.Baumbach,
R.Sutphen,
J.L.Pickard-Brzosowicz,
K.L.Nathanson,
A.Sali,
D.Goldgar,
F.J.Couch,
P.Radice,
and
A.N.Monteiro
(2007).
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
|
| |
Cancer Res, 67,
1494-1501.
|
 |
|
|
|
|
 |
M.Laufer,
S.V.Nandula,
A.P.Modi,
S.Wang,
M.Jasin,
V.V.Murty,
T.Ludwig,
and
R.Baer
(2007).
Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
|
| |
J Biol Chem, 282,
34325-34333.
|
 |
|
|
|
|
 |
P.Vasickova,
E.Machackova,
M.Lukesova,
J.Damborsky,
O.Horky,
H.Pavlu,
J.Kuklova,
V.Kosinova,
M.Navratilova,
and
L.Foretova
(2007).
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
|
| |
BMC Med Genet, 8,
32.
|
 |
|
|
|
|
 |
R.Karchin,
A.N.Monteiro,
S.V.Tavtigian,
M.A.Carvalho,
and
A.Sali
(2007).
Functional impact of missense variants in BRCA1 predicted by supervised learning.
|
| |
PLoS Comput Biol, 3,
e26.
|
 |
|
|
|
|
 |
G.Chinnadurai
(2006).
CtIP, a candidate tumor susceptibility gene is a team player with luminaries.
|
| |
Biochim Biophys Acta, 1765,
67-73.
|
 |
|
|
|
|
 |
J.Liu,
Y.Pan,
B.Ma,
and
R.Nussinov
(2006).
"Similarity trap" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains.
|
| |
Structure, 14,
1811-1821.
|
 |
|
|
|
|
 |
X.Yu,
S.Fu,
M.Lai,
R.Baer,
and
J.Chen
(2006).
BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP.
|
| |
Genes Dev, 20,
1721-1726.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|